非磺脲类降糖药的研究现状与临床评价  

Study and Clinical Evaluation of Non-sulfonylureas Antidiabetic Drugs

作　　者：张石革[1] 宋菲[1] 

机构地区：[1]北京大学北京积水潭医院,北京市100035

出　　处：《中国医院用药评价与分析》2005年第1期11-14,共4页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的 :非磺脲类降糖药有别于磺酰脲类 ,不仅在结构上且表现在作用靶位上 ,其快速释放又快速关闭 ,对餐时、餐后血糖有显著的控制作用 ,不累及胰岛 β细胞 ,不导致胰岛素分泌耗竭 ,被誉为“餐时血糖调节剂”。本文旨在回顾此类药物的研究进展、临床应用 ,并对其临床疗效及安全性进行评价。方法 :采用国内、外文献综述方法。结果与结论 :大量的循证医学研究证实 ,非磺脲类降糖药具有鲜明的特点 ,降低餐后血糖迅速 ;同时与二甲双胍作用互补 ,为餐时高血糖、孤立性餐后高血糖、胰岛素分泌第 1时相障碍者和饮食不规律者的血糖控制确立一道坚实的屏障。OBJECTIVE:Non-sulfonylureas antidiabetic drugs(NSUR) are different from Sulfonylureas not only in the structure but also in target site of the action. The feature of quick release and quick close has marked control effect on mealtime and postprandial blood sugar(PPBS).This kind of drugs don't involve in beta cell of islet and lead to exhause of insulin secretion ,so they are called “mealtime blood sugar regulators'. This paper is to look back research progress and clinical application of this kind of drugs, and evaluate their clinical efficiency and safety. METHODS: By reviewing recent literatures at home and abroad. RESULTS & CONCLUSION: Large numbers of indication-based medical studies have proved that non-sulfonylureas antidiabetic drugs have obvious feature,they can quickly decrease PPBS and have complemental action to dimethylbiguanide. They have set up a solid barricade for the patients with mealtime hyperglycemia, isolated postprandial hyperglycemia, first phase disturbance of insulin secretion and blood sugar control of irregular meal.

关 键 词：磺脲类降糖药 餐后血糖 临床评价 临床应用 胰岛素分泌 靶位 餐时血糖调节剂 关闭 屏障 障碍 

分 类 号：R587[医药卫生—内分泌] R977.15[医药卫生—内科学]